Literature DB >> 26064345

Down-regulation of tissue microRNA-126 was associated with poor prognosis in patients with cutaneous melanoma.

Nengxing Lin1, Yu Zhou1, Xin Lian1, Yating Tu1.   

Abstract

BACKGROUND: MiR-126 is frequently downregulated in a variety of malignancies and acts as a potential tumor suppressor. It also played a tumor suppressor role in human melanoma through the direct or indirect repression of several key oncogenic molecules.
METHODS: qRT-PCR assay was performed to examine the expression of miR-126. Associations between miR-126 expression and various clinicopathological characteristics were analyzed using the χ(2) test. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysis.
RESULTS: Significant differences for miR-126 expression were shown between dysplastic nevi and primary cutaneous melanoma (P<0.01), between primary melanoma and metastatic cutaneous melanomas (P<0.01), and between primary cutaneous melanomas and metastatic cutaneous melanomas (P<0.001). The patients with low miR-126 expression showed shorter 5-year overall survival than those with high miR-126 expression (P=0.039; log-rank test). Multivariate regression analysis showed that the status of miR-126 expression was an independent prognostic factor overall survival (HR=3.782, 95% CI: 2.479-16.334, P=0.005).
CONCLUSION: The status of miR-126 might be an independent prognostic factor for patients with cutaneous melanoma.

Entities:  

Keywords:  biomarker; cutaneous melanoma; microRNA-126; prognosis

Year:  2015        PMID: 26064345      PMCID: PMC4443179     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  20 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival.

Authors:  Tom Donnem; Kenneth Lonvik; Katrine Eklo; Thomas Berg; Sveinung W Sorbye; Khalid Al-Shibli; Samer Al-Saad; Sigve Andersen; Helge Stenvold; Roy M Bremnes; Lill-Tove Busund
Journal:  Cancer       Date:  2011-01-24       Impact factor: 6.860

3.  Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish Population-based Register Study 1989-2011.

Authors:  Christiane Bay; Anne Mette Tranberg Kejs; Hans H Storm; Gerda Engholm
Journal:  Cancer Epidemiol       Date:  2014-11-04       Impact factor: 2.984

Review 4.  MicroRNAs: opening a new vein in angiogenesis research.

Authors:  Jason E Fish; Deepak Srivastava
Journal:  Sci Signal       Date:  2009-01-06       Impact factor: 8.192

5.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

6.  miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin.

Authors:  Qing Yu; Shan-Ling Liu; He Wang; Gang Shi; Pei Yang; Xin-Lian Chen
Journal:  Asian Pac J Cancer Prev       Date:  2014-01

Review 7.  Melanoma: adjuvant therapy and other treatment options.

Authors:  Alicia Terando; Michael S Sabel; Vernon K Sondak
Journal:  Curr Treat Options Oncol       Date:  2003-06

8.  Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.

Authors:  Xiaohong Wang; Shuang Tang; Shu-Yun Le; Robert Lu; Janet S Rader; Craig Meyers; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

9.  Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of US women.

Authors:  Abrar A Qureshi; Mingfeng Zhang; Jiali Han
Journal:  J Epidemiol       Date:  2011-04-23       Impact factor: 3.211

10.  Breast cancer metastasis: a microRNA story.

Authors:  Massimo Negrini; George Adrian Calin
Journal:  Breast Cancer Res       Date:  2008-03-26       Impact factor: 6.466

View more
  4 in total

Review 1.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

Review 2.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

3.  Prognostic significance of miR-126 in various cancers: a meta-analysis.

Authors:  Yuanli Dong; Chengrui Fu; Hui Guan; Zicheng Zhang; Tao Zhou; Baosheng Li
Journal:  Onco Targets Ther       Date:  2016-04-28       Impact factor: 4.147

4.  miR-126 Decreases Proliferation and Mammosphere Formation of MCF-7 and Predicts Prognosis of ER+ Breast Cancer.

Authors:  Zahraa S Msheik; Farah J Nassar; Ghada Chamandi; Abdul Rahman Itani; Emanuala Gadaleta; Claude Chalala; Nisreen Alwan; Rihab R Nasr
Journal:  Diagnostics (Basel)       Date:  2022-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.